HONG KONG (Reuters/IFR) - Chinese Nasdaq-listed biotech BeiGene Ltd has raised $903 million after pricing its secondary listing in Hong Kong - the first under new exchange rules - near the top of an indicative range, three people close to the deal said on Thursday.
from Reuters: Health News https://ift.tt/2MbSZZU
No comments:
Post a Comment